-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Acute myeloid leukemia (AML) is a life-threatening disease in which neutrogenic granulocytes, alkaline granulocytes, eosinophils, and monocytes have premeditated cell malignants and rapidly replace normal bone marrow cells.
AML is the most common type of leukemia in adults, it can affect people of all ages.
, AML is caused by chemotherapy or radiotherapy used to treat another cancer.
Recently, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb's Onureg (azacitidine) for the treatment of acute myeloid leukemia (AML) in adults: CR patients who have been fully remissiond for the first time after intensive induction chemotherapy (CR) or who have not completed the recovery of blood cell counts can continue to use azacline therapy.
in the Phase III QUAZAR AML-001 study, the total lifetime (OS) of patients in the Onureg treatment group improved significantly compared to placebo, which was the main endpoint of the study.
the median total survival (OS) was greater than two years in patients in the Onureg treatment group, while in patients treated with a placebo, the median total survival (OS) was 14.8 months.
lead researcher on the trial, Andrew Wei, said: "Continued use of Onureg therapy showed overall survival benefits in adults with the first complete remission of AML."
.
